Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia
Chaitra Ujjani(University of Washington), Philip A. Thompson(The Royal Melbourne Hospital), Susan O’Brien(University of California, Irvine), Allison Winter(Cleveland Clinic), Catherine Lai(University of Pennsylvania), David M. Koelle(Infectious Disease Research Institute), Kerry J. Laing(University of Washington), Catherine M. Broome(Georgetown University), Deborah M. Stephens(University of North Carolina at Chapel Hill), Brian Tu(University of Washington), Kerry A. Rogers(The Ohio State University), Genesis Quezada(Fred Hutch Cancer Center), Mazyar Shadman(University of Washington), Georgios Pongas(University of Miami), Tyler Sorensen(Fred Hutch Cancer Center), Kelsey Launchbury(Fred Hutch Cancer Center), Alexander L. Greninger(University of Washington), Matthew S. Davids(Dana-Farber Cancer Institute), Carlissa J. Burrow(University of Washington), Alexey V. Danilov(City of Hope), Amy Sperling(Fred Hutch Cancer Center), Ted Gooley(Fred Hutch Cancer Center), Stephen E. Spurgeon(Oregon Health & Science University), Haiying Zhu(Second Military Medical University), Tanya Siddiqi(City Of Hope National Medical Center)
Cited by 12
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k